Allison Betof Warner, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Warner’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A184101 · Current
Licensed to practise in California · since 2023 · expires 2027-02-28 · Duke University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$49,174
Medicare paid this office $49,174 for 91 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 43 | $14,828 | $130 |
| Return visit (30+ min) | 51 | $11,367 | $85 |
| Return visit (30+ min) | 31 | $6,503 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $3,206 | $107 |
| New patient visit (60+ min) | 16 | $2,635 | $165 |
See all 9 services
| Long return visit (40+ min) | 43 | $14,828 | $130 |
| Return visit (30+ min) | 51 | $11,367 | $85 |
| Return visit (30+ min) | 31 | $6,503 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $3,206 | $107 |
| New patient visit (60+ min) | 16 | $2,635 | $165 |
| Long return visit (40+ min) | 12 | $2,441 | $174 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 55 | $2,387 | $15 |
| New patient visit (45+ min) | 13 | $1,571 | $121 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 20 | $438 | $15 |
Who their Medicare patients are
91 Original Medicare patients in 2024. Average age 74 · Women 35% · Also on Medicaid 18% · Health risk score 2.62. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 75% · Diabetes 32% · Cancer 32% · Coronary heart disease 30% · Chronic kidney disease 29% · Atrial fibrillation 24% · Depression 22% · Heart failure 16% · Stroke 15% · Dementia 12%.
The office billed $150,079, Medicare allowed $62,728 and paid $49,174; for 600 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 91 | 600 | 74 | 2.62 | $150,079 | $49,174 |
| 2023 | 78 | 260 | 74 | 1.80 | $95,472 | $28,297 |
| 2022 | 114 | 427 | 75 | 2.22 | $259,720 | $44,214 |
| 2021 | 94 | 300 | 73 | 2.45 | $182,370 | $31,319 |
| 2020 | 88 | 268 | 73 | 2.87 | $133,340 | $21,065 |
| 2019 | 24 | 63 | 73 | 1.15 | $44,975 | $6,644 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 29 | $7,913 | $132 |
| Return visit (30+ min) | 29 | $5,105 | $90 |
| New patient visit (60+ min) | 28 | $4,678 | $167 |
| New patient visit (45+ min) | 16 | $1,948 | $122 |
2022: 4 services
| Long return visit (40+ min) | 36 | $13,337 | $132 |
| Return visit (30+ min) | 57 | $12,913 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $11,748 | $93 |
| New patient visit (60+ min) | 22 | $3,750 | $170 |
2021: 4 services
| Return visit (30+ min) | 47 | $11,286 | $91 |
| Long return visit (40+ min) | 37 | $10,426 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $4,281 | $95 |
| New patient visit (60+ min) | 14 | $2,433 | $174 |
2020: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $5,393 | $95 |
| Return visit (30+ min) | 35 | $5,150 | $69 |
| Long return visit (40+ min) | 20 | $3,477 | $99 |
| New patient visit (60+ min) | 11 | $1,555 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,182 | $66 |
2019: 3 services
| New patient visit (60+ min) | 18 | $2,704 | $150 |
| Long return visit (40+ min) | 15 | $2,661 | $99 |
| Return visit (30+ min) | 12 | $1,187 | $70 |
Drugs they prescribed that Part D paid
$318,783
Pharmacies billed $318,783 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 112) in 2024. At or below the middle of the specialty; the typical medical oncology clinician is at 6%.
87 generic and 25 brand-name prescriptions · $318,783 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Mekinist | 11 | $163,714 | $14,883 |
| Tafinlar | 11 | $151,522 | $13,775 |
| Prednisone | 31 | $298 | $10 |
Year by year
| 2024 | 112 | 31 | 0% (0) | 22% | $318,783 |
| 2023 | 75 | 27 | None | 53% | $482,559 |
| 2022 | 111 | 25 | None | 53% | $723,815 |
| 2021 | 147 | 29 | None | 52% | $949,033 |
| 2020 | 114 | 34 | None | 39% | $184,417 |
| 2019 | 34 | 14 | None | None | $48,069 |
| 2017 | 16 | None | 0% (0) | None | $1,112 |
| 2016 | 100 | 32 | None | 14% | $3,952 |
| 2015 | 143 | 22 | None | None | $10,842 |
| 2014 | 93 | 11 | None | 15% | $2,697 |
| 2013 | 37 | 11 | None | None | $1,012 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Braftovi | 11 | $151,331 | $13,757 |
| Prednisone | 11 | $91 | $8 |
2022: 3 drugs
| Braftovi | 24 | $371,150 | $15,465 |
| Mektovi | 23 | $351,196 | $15,269 |
| Prednisone | 24 | $112 | $5 |
2021: 5 drugs
| Mektovi | 31 | $387,315 | $12,494 |
| Braftovi | 26 | $330,820 | $12,724 |
| Ondansetron | 13 | $204 | $16 |
| Prednisone | 23 | $176 | $8 |
| Dexamethasone | 11 | $91 | $8 |
2020: 2 drugs
| Prednisone | 18 | $161 | $9 |
| Sodium Chloride | 13 | $65 | $5 |
2019: 1 drug
| Prednisone | 11 | $81 | $7 |
2015: 3 drugs
| Crestor | 12 | $2,529 | $211 |
| Simvastatin | 11 | $79 | $7 |
| Lisinopril | 12 | $62 | $5 |
2014: 3 drugs
| Atorvastatin | 11 | $212 | $19 |
| Lisinopril | 12 | $70 | $6 |
| Atenolol | 13 | $68 | $5 |
Money from drug and device companies
$21,064 in 2025
| 2025 | 7 | 19 | $19,585 | $21,064 |
| 2024 | 7 | 27 | $16,740 | $19,588 |
| 2023 | 5 | 40 | $27,265 | $31,307 |
| 2022 | 2 | 4 | $3,352 | $3,483 |
| 2021 | 2 | 2 | $2,510 | $2,510 |
| 2020 | 1 | 1 | $1,250 | $1,250 |
| 2019 | 2 | 2 | None | $219 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Immunocore | Kimmtrak | $11,439 | 6 payments
|
| Merck Sharp & Dohme | None | $5,120 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $2,865 | 1 payment
|
| Adaptimmune | None | $1,239 | 2 payments
|
| Iovance Biotherapeutics | Amtagvi | $288 | 6 payments
|
| Ge Healthcare | None | $81 | 2 payments
|
See all 19 published payments
| Immunocore | Honoraria · 2025-12-16 | Kimmtrak | $5,200 |
| Immunocore | Meals · 2025-12-09 | Kimmtrak | $21 |
| Immunocore | Meals · 2025-12-09 | Kimmtrak | $15 |
| Immunocore | Travel · 2025-12-09 | Kimmtrak | $63 |
| Merck Sharp & Dohme | Consulting · 2025-12-03 | None | $5,120 |
| Iovance Biotherapeutics | Meals · 2025-11-08 | Amtagvi | $34 |
| Ge Healthcare | Meals · 2025-11-06 | None | $41 |
| Ge Healthcare | Meals · 2025-11-06 | None | $41 |
| Iovance Biotherapeutics | Meals · 2025-10-24 | Amtagvi | $18 |
| Iovance Biotherapeutics | Meals · 2025-10-24 | Amtagvi | $57 |
| Iovance Biotherapeutics | Meals · 2025-09-06 | Amtagvi | $41 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-06-27 | None | $2,865 |
| Immunocore | Honoraria · 2025-05-15 | Kimmtrak | $5,200 |
| Immunocore | Travel · 2025-05-06 | Kimmtrak | $939 |
| Kite Pharma | Meals · 2025-04-21 | Yescarta | $31 |
| Adaptimmune | Honoraria · 2025-02-17 | None | $1,200 |
| Adaptimmune | Meals · 2025-02-15 | None | $39 |
| Iovance Biotherapeutics | Meals · 2025-02-13 | Amtagvi | $56 |
| Iovance Biotherapeutics | Meals · 2025-02-12 | Amtagvi | $81 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $19,588
| Array Biopharma | Braftovi | $7,261 | 5 payments
|
| Merck Sharp & Dohme | Keytruda | $6,652 | 7 payments
|
| Genmab U.S. | Epkinly | $3,580 | 3 payments
|
| Novartis Pharmaceuticals | Mekinist | $1,415 | 2 payments
|
| Iovance Biotherapeutics | Amtagvi | $433 | 6 payments
|
| Immunocore | Kimmtrak | $125 | 2 payments
|
| Pfizer | Lorbrena | $124 | 2 payments
|
2023: $31,307
| Merck Sharp & Dohme | Keytruda | $16,183 | 17 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $8,692 | 12 payments
|
| Array Biopharma | Braftovi | $4,346 | 7 payments
|
| Novartis Pharmaceuticals | None | $2,035 | 3 payments
|
| Eisai | None | $51 | 1 payment
|
2022: $3,483
| E.R. Squibb & Sons L.L.C. | Opdivo | $3,418 | 2 payments
|
| Novartis Pharmaceuticals | Mekinist | $65 | 2 payments
|
2021: $2,510
| Array Biopharma | Braftovi | $1,260 | 1 payment
|
| Novartis Pharmaceuticals | Mekinist | $1,250 | 1 payment
|
2020: $1,250
| Novartis Pharmaceuticals | Mekinist | $1,250 | 1 payment
|
2019: $219
| Novartis Pharmaceuticals | None | $122 | 1 payment
|
| Array BioPharma | None | $97 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Iovance Biotherapeutics, Inc. · Iov-Eap-402 · 2025 | Their institution | $70,829 |
| Daiichi Sankyo Company LTD · Ds1055-A-J101 · 2023 | Their institution | $53,234 |
| Iovance Biotherapeutics, Inc. · Amtagvi · 2025 | Their institution | $28,800 |
| Daiichi Sankyo Company LTD · Ds1055-A-J101 · 2021 | Their institution | $25,375 |
| Daiichi Sankyo Inc. · Ds1055-A-J101 · 2021 | Their institution | $25,375 |
| ARRAY BIOPHARMA INC · A Phase 2 Openlabel Randomized Multicenter Trial of Encorafenib Binimetinib Evaluating A Standarddose and A Highdose Regimen in Patients With Brafv600mutant Melanoma Brain Metastasis · 2020 | Their institution | $19,835 |
| ARRAY BIOPHARMA INC · A Phase 2 Openlabel Randomized Multicenter Trial of Encorafenib Binimetinib Evaluating A Standarddose and A Highdose Regimen in Patients With Brafv600mutant Melanoma Brain Metastasis · 2022 | Their institution | $3,266 |
| NOVARTIS PHARMACEUTICALS CORPORATION · Publication Support Provided in Connection With Heor Research · 2022 | This clinician | $2,683 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 89.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1174961908
- Licence
- CA A184101, NY 283244California A184101: Current · expires 2027-02-28
- Trained
- Duke University School of Medicine, 2013
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X)
- Mailing address
- 900 Blake Wilbur Drive, 3rd Floor, Stanford, CA, 94305
- NPI first listed
- 2013-06-14
- NPI last updated
- 2026-06-19
- NPI record certified
- 2026-06-19
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1275 York Ave, New York, NY, 10065